Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Patient Satisfaction 2Urologic Neoplasms 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Radiation Injuries 1Patient Preference 1Patient Acceptance of Health Care 1Osteosarcoma 1Osteitis Deformans 1Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × delta 24-sterol reductase × Clear all
NCT01882231 2017-05-08

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled
Sarcoma

Bone Neoplasms, Osteitis Deformans, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡